News Article | February 28, 2017
BARCELONA, Spain--(BUSINESS WIRE)--NoviFlow Inc., a leading provider of high-performance OpenFlow-based switching and routing solutions, and Stordis GmbH., a premier independent distributor of Open Networking infrastructure and storage solutions, today announce that Stordis has become an authorized distributor of NoviFlow’s products in Europe. With this agreement, Stordis will offer to its customers NoviFlow’s line of high-performance fully programmable forwarding planes that leverage the advanced packet handling capabilities of network processors to significantly boost throughput, offer enhanced filtering options at line rates up to 100 Gbps, and support for up to 16 million simultaneous flows. NoviFlow will be demonstrating its NoviSwitch products with live SDN-based security applications at Mobile World Congress 2017, February 27th to March 2nd in Barcelona. We invite all interested parties to come visit us at Stand 7H40. According to Dominique Jodoin, President and CEO of NoviFlow: “The majority of our customers are Tier 1 Carriers who are deploying our SDN networking solutions in order to modernize their networks. These customers usually go through a process of first trialing competing SDN solutions based on ASIC or X86 technology, and then, when these options fail to adequately provide both programmability and performance, they select NoviFlow solutions which can deliver both in one package. NoviSwitch forwarding planes are the ideal platform for sophisticated applications that can make comprehensive use of a fully programmable forwarding plane running at Ethernet line rates. Our range of NoviSwitches also supports very large table capacities and management features designed to ease large-scale deployments, making NoviFlow’s NoviWare the perfect solution for Tier 1 carriers, network infrastructure providers, and enterprises. We are honored to collaborate with such a distinguished partner as STORDIS to expand our mutual business in the European region.” The NoviSwitch line features the NoviWare switching software, NoviFlow’s high-performance OpenFlow forwarding plane software for use in mission-critical deployments. NoviWare provides the industry’s broadest support of the OpenFlow specification, including all OpenFlow 1.3 and 1.4 actions, instructions and match fields, and key OpenFlow 1.5 features. NoviSwitches leverage the same Network Processors used in expensive network routers to offer switching, routing, tunneling, monitoring, filtering, metering, service chaining, load balancing, time stamping, cybersecurity and other flow-handling capabilities at line-rate, as part of network fabric and at a significantly reduced cost. Alexander Jeffries, CEO at STORDIS says: “NoviFlow’s products deliver on the promise of software defined networking by providing a powerful, agile and fully programmable forwarding plane that can support multiple network services such as BGP, MPLS and LDP, service chaining of VNFs for 4G/5G EPC, DPI, Firewalling, Load Balancing, Security, and Network Address Translation. We see our partnership with NoviFlow truly raising the performance and functionality bar in SDN and as a major step forward in the realization of the fully programmable network!” ABOUT NOVIFLOW NoviFlow Inc. provides high-performance OpenFlow-based switching solutions to network carriers, data center operators and enterprises seeking greater control, security and flexibility over their networks. NoviFlow has offices in Montreal, Sunnyvale and Seattle, and representatives in Asia Pacific, Europe and the Middle East. For more information, please visit http://noviflow.com/. Follow NoviFlow on Twitter @NoviFlowInc. ABOUT STORDIS STORDIS is the leading independent distributor of Open Networking Infrastructure and Storage Solutions. For resellers across Europe and beyond, STORDIS offers peerless expertise on combining the next generation of high-performance hardware, together with software defined networking and storage technologies that are built on open source and open standards. With a strong vertical market focus, STORDIS’ six business units provide customers within: Media & Broadcast, Telecommunications, Service Providers, Financial Trading, Research and Academia, and the Cyber Security industry, with experienced, specialist technical advice and a real understanding of their business needs. STORDIS’ head office and research center is located in Stuttgart, Germany, with additional sales offices in London and Paris.
News Article | February 15, 2017
Aricent Traffic Detection Function (TDF) provides communication service providers an opportunity to capitalize on analytics for traffic optimization, charging and content manipulation, working hand in hand with the policy management system REDWOOD CITY, CA--(Marketwired - Feb 14, 2017) - Aricent, a global design and engineering company, and Rohde & Schwarz Cybersecurity, leading vendor of network analytics solutions, have announced a technology solution to further enhance quality of service, traffic optimization and service charging. Aricent's Traffic Detection Function capability now incorporates the deep packet inspection (DPI) engine R&S® PACE 2, a state-of-the art DPI software library that uses different technologies (including pattern matching, behavioral, heuristic and statistical analysis) to classify network protocols and applications. Network equipment vendors as well as network and telecom operators around the world rely on R&S®PACE 2 to get full visibility into IP-based network traffic. Rohde & Schwarz Cybersecurity network security technology will be made available as part of Aricent's Evolved Packet Core (EPC) Software Framework and Aricent's Intelligent Switching Solution. R&S®PACE 2 has been integrated using Aricent's dynamic filtering capability to help mobile operators and service providers raise situational awareness, activate differential bandwidth control and optimize network resources. Rohde & Schwarz Cybersecurity and Aricent plan to collaborate on various areas including: "We see a significant demand from our customers to bring flexible and programmable network services to core networks. We are thrilled to be working with Aricent, who have built its reputation in the data-center, mobile and wireless market. Together we can offer mobile operators and service providers the ability to reduce the time to market for security and network management capabilities," said Ulf Lange, Director of DPI. "Service providers must focus on value and not just services. Ultimately, shaping network traffic and controlling its behavior helps bring intelligence to the customer experience," said Walid Negm, chief technology officer for Aricent. "The outcome is more adaptive resources that can for example deliver personalized streaming video, help parents better protect their children from harmful content or empower enterprises through be-spoke digital services. Certainly, operators themselves will be prepared to drive new revenue opportunities." Meet Aricent at Mobile World Congress at the executive meeting room: 2UP.B7EMR, Upper Walkway, Zone B, where Aricent will demonstrate expertise in Converged IoT solutions, Mobile Edge/5G, Service Management & Orchestration/NFV and NB-IoT and turnkey technologies. Visit Rohde & Schwarz Cybersecurity at Mobile World Congress in Barcelona at booth 6C40 and find out how to enhance your product with the protocol and application classification engine R&S® PACE 2. About Aricent Aricent is a global design and engineering company innovating for the digital era. With more than 12,000 talented designers and engineers and over 25 years of experience, we help the world's leading companies solve their most important business and technology innovation challenges -- from Customer to Chip. About Rohde & Schwarz Cybersecurity Rohde & Schwarz Cybersecurity is an IT security company that protects companies and public institutions around the world against cyberattacks. The company develops and produces technologically leading solutions for information and network security, including highly secure encryption solutions, next-generation firewalls and software for network analysis and endpoint security. Find out more: https://ipoque.com
News Article | February 24, 2017
IRVINE, CA--(Marketwired - Feb 24, 2017) - Cannabis Science, Inc. ( : CBIS), a U.S. company specializing in the development of cannabis-based medicines, is pleased to announce updates on the proposed self-medicating DPI Inhalation Device for Asthma/COPD and our Cannabinoid infused pain patch. The Company is working on the final packaging for the Cannabinoid-based Pain Patches and will roll out to partner dispensaries in the Los Angeles area very soon, joining the existing Cannabis Science product line. "Cannabis Science would also like to acknowledge President Donald J. Trump for his support and recognition of the benefits of Medical Cannabis; it is a welcomed message for Cannabis Science to see the President is supportive of Medical Cannabis and we believe this will strengthen the Medical Cannabis initiative across this great nation and will give even more states the desire to employ Cannabinoids into the arsenal to fight disease," stated CEO Mr. Raymond C. Dabney. The MDI Inhaler is one of the first medical based Cannabinoid inhalers to hit the market, and the wide range of other cannabinoid products being systematically released by the company is showing a very high market acceptance and brand equity growth. Local and nationwide dispensaries are expressing interest in carrying Cannabis Science's new products, and new relationships are being built while the existing ones are being strengthened. This is one of the best growth signs any Company could ask for its Cannabinoid medical based products. As previously mentioned, research into the development of a DPI Inhaler looks very promising; the method of delivery and dosage amounts have been established; below CBIS have provided guidance to show what led us to decide a long-term therapy medication was needed for patients in later stages and advanced cases of these ailments and diseases. Dry powder inhalers are a group of inhalers that have the medication in very fine dry powder format. They are classified into single dose devices, multiple unit dose devices and multi dose devices. These tend to be more popular with patients because they are all breath actuated. They are usually used for long-term asthma management. Inhalers used for asthma/COPD can be classified into two categories: Metered dose inhalers (MDIs) and Dry powder inhalers (DPIs). Metered dose inhalers are usually used as asthma rescue inhalers or reliever medicines. There are breath-actuated auto-inhalers that release the medication when you breathe in, and there are non breath-actuated pressurized inhalers in which the medication is released by pushing the canister down into the holder. They are all bronchodilators and are either short or long acting beta agonist inhalers or inhaled corticosteroids. The active ingredients in MDI inhalers are dissolved or suspended in a propellant, a mixture of propellants, or a mixture of solvents and they are delivered via a compact pressurized aerosol dispenser. The dispenser can hold about several hundred metered doses of the medication. DPI inhalers contain the medication in a fine dry powder format and the medication is delivered to the lungs as the patient inhales through it. It contains the medication without any propellants. There are pre-metered DPIs which contain previously measured doses in blisters, capsules, etc. and they are inserted into the device during the manufacturing process or by the patient before use. The dose is inhaled directly from the pre-metered unit or it might be transferred to a chamber before being inhaled. Updates on product launches are expected to be released in the near future, and these products will soon be available in several Los Angeles area dispensaries. For a list of partner dispensaries, call the Company at 1 (888) 263-0832. Cannabis Science, Inc., takes advantage of its unique understanding of metabolic processes to provide novel treatment approaches to a number of illnesses for which current treatments and understanding remain unsatisfactory. Cannabinoids have an extensive history dating back thousands of years, and currently, there are a growing number of peer-reviewed scientific publications that document the underlying biochemical pathways that cannabinoids modulate. The Company works with leading experts in drug development, medicinal characterization, and clinical research to develop, produce, and commercialize novel therapeutic approaches for the treatment for illnesses caused by infections as well as for age-related illness. Our initial focus is on skin cancers, HIV/AIDS, and neurological conditions. The Company is proceeding with the research and development of its proprietary drugs as a part of this initial focus: CS-S/BCC-1, CS-TATI-1, and CS-NEURO-1, respectively. This Press Release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Act of 1934. A statement containing words such as "anticipate," "seek," intend," "believe," "estimate," "expect," "project," "plan," or similar phrases may be deemed "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Some or all of the events or results anticipated by these forward-looking statements may not occur. Factors that could cause or contribute to such differences include the future U.S. and global economies, the impact of competition, and the Company's reliance on existing regulations regarding the use and development of cannabis-based drugs. Cannabis Science, Inc., does not undertake any duty nor does it intend to update the results of these forward-looking statements. Safe Harbor Statement. The Private Securities Litigation Reform Act of 1995 provides a 'safe harbor' for forward looking statements. Certain of the statements contained herein, which are not historical facts are forward looking statements with respect to events, the occurrence of which involved risks and uncertainties. These forward-looking statements may be impacted, either positively or negatively, by various factors. Information concerning potential factors that could affect the company are detailed from time to time in the company's reports filed with the Securities and Exchange Commission.
News Article | February 15, 2017
- Developers of Networking and Security Products Benefit From an Enhanced Deep Packet Inspection (DPI) Software Development kit and new Value-added Software Modules. STOCKHOLM, Feb. 15, 2017 /PRNewswire/ -- Enea® (NASDAQ OMX Nordic:ENEA) today announced the launch of Qosmos® ixEngine 5.3, a Deep Packet Inspection (DPI) library for software developers who wish to embed detailed, real-time visibility into their networking or security products. With Qosmos® ixEngine 5.3, developers benefit from unique value-added software modules and an enhanced software development kit. Qosmos® ixEngine 5.3 is available immediately for limited deployment and in Q2 2017 for general deployment. "Qosmos ixEngine 5.3 makes it even easier for developers to build applications, by leveraging significant improvements to the development kit and thanks to the addition of unique value-added software modules", said Thibaut Bechetoille, President of Qosmos. "These modules are comparable to prefab components in the construction industry, and Qosmos, already recognized as an industry innovator, is leading a similar trend in high-tech." Qosmos ixEngine is the de facto industry-standard for IP classification and metadata extraction engine based on Deep Packet Inspection (DPI). Networking vendors, security specialists, and cloud service providers widely use Qosmos to gain application visibility, accelerate development, strengthen capabilities of new solutions, and benefit from continuous protocol signature updates. Qosmos is a division of Enea since December 2016. Enea is a global supplier of network software platforms and world class services, with a vision of helping customers develop amazing functions in a connected society. We are committed to working together with customers and leading hardware vendors as a key contributor in the open source community, developing and hardening optimal software solutions. Every day, more than three billion people around the globe rely on our technologies in a wide range of applications in multiple verticals – from Telecom and Automotive, to Medical and Avionics. We have offices in Europe, North America and Asia, and are listed on NASDAQ OMX Nordic Exchange Stockholm AB. Discover more at www.enea.com and start a conversation at email@example.com. Enea®, Enea OSE®, Netbricks®, Polyhedra®, Zealcore®, Enea® Element, Enea® Optima, Enea® LINX, Enea® Accelerator, Enea® dSPEED Platform and COSNOS® are registered trademarks of Enea AB and its subsidiaries. Enea OSE®ck, Enea OSE® Epsilon, Enea® Optima Log Analyzer, Enea® Black Box Recorder, Polyhedra® Lite, Enea® System Manager, Enea® ElementCenter NMS, Enea® On-device Management and Embedded for LeadersTM are unregistered trademarks of Enea AB or its subsidiaries. Any other company, product or service names mentioned above are the registered or unregistered trademarks of their respective owner. All rights reserved. © Enea AB 2017. This information was brought to you by Cision http://news.cision.com http://news.cision.com/enea-ab/r/enea-announces-qosmos-ixengine-5-3--confirming-industry-leadership-in-ip-classification-and-metadata,c2189064 The following files are available for download:
News Article | February 28, 2017
The accelerating consumer acceptance and expanding legalization of legal marijuana as well as cannabis infused products and its medicinal applications has resulted in many new opportunities for cannabis based companies and operators. Consumers can now obtain the benefits of legal marijuana without have to smoke the substance as popularity grows for CBD infused products from skin care to medicinal therapies to infused consumer goods and water products. Cannabis, medicinal marijuana, CBD infused product companies include: Puration, Inc. (OTC: PURA), OWC Pharmaceutical Research Corp. (OTC: OWCP), Cannabis Science, Inc. (OTC: CBIS), Medical Marijuana, Inc. (OTC: MJNA) and GrowBlox Sciences, Inc. (OTC: GBLX). Puration, Inc. (OTC: PURA) and Alkame Holdings, Inc. (ALKM) today announced that the two Companies will partner to introduce a second EVERx Bottled Water product at the upcoming Annual Arnold Sports Festival (formerly the 'Arnold Classic' named for Arnold Schwarzenegger) in Columbus, Ohio this week, starting March 2nd, 2017. PURA previously announced the launch of its EVERx CBD Infused Bottled Water to take place at the Arnold. Today, the two companies are announcing that PURA will private label ALKM's patented Alkaline Water under the EVERx brand name. Both EVERx CBD Infused Bottled Water and EVERx Alkaline Bottled Water will be launched at the Arnold. Title contender, number three ranked UFC MMA women's bantamweight fighter, Julianna Peña will be the EVERx Brand Spokesperson at the Arnold for both EVERx CBD Infused Bottled Water and EVERx Alkaline Water. Read this and more news for PURA at: http://marketnewsupdates.com/news/pura.html To learn more about the EVERx Brand Product Launch at the Arnold Sports Festival, follow this link EVERx BRAND LAUNCH AT THE ARNOLD SPORTS FESTIVAL ALKM's patented technology alters the structure of water, producing a combination of characteristics that are unprecedented in the beverage industry. The ALKM technology breaks down the hydrogen bonds, reducing water's cluster size, providing a more efficient delivery system for the CBD in the EVERx CBD Infused Bottled Water, and the ALKM technology includes an optimal alkaline pH level formulated with antioxidants and electrolytes so that the EVERx Alkaline Bottled water can deliver most effective hydration available in the alkaline water market. In other cannabis developments of note: OWC Pharmaceutical Research Corp. (OTCQB: OWCP), an Israeli-based developer of cannabinoid-based therapies targeting a variety of different medical conditions and disorders, yesterday announced it has received Institutional Review Board (IRB) approval to conduct safety testing on its proprietary topical crème compound for the treatment of psoriasis and related skin conditions. The approval follows the Company's February 1, 2017 8K filing announcing an extension to the size and scope of its efficacy study on the same compound, which began in November 2106. Cannabis Science, Inc. (OTC: CBIS), a U.S. company specializing in the development of cannabis-based medicines, announced late last week updates on the proposed self-medicating DPI Inhalation Device for Asthma/COPD and our Cannabinoid infused pain patch. The Company is working on the final packaging for the Cannabinoid-based Pain Patches and will roll out to partner dispensaries in the Los Angeles area very soon, joining the existing Cannabis Science product line. Medical Marijuana, Inc. (OTC: MJNA), the first publicly traded cannabis company in the United States, subsidiary, HempMeds® Brasil announced last week that the Brazilian government has authorized a doctor's prescription for the Company's hemp cannabidiol (CBD) oil product Real Scientific Hemp Oil™ (RSHO™) to treat patients in the country suffering from Multiple Sclerosis. This marks the first time that Brazil's National Health Surveillance Agency ANVISA has granted the filling of a prescription for RSHO™ to specifically help patients combat the effects of Multiple Sclerosis. Per the Multiple Sclerosis International Federation (MSIF), more than 2.5million people worldwide are affected by MS, a progressive disease of the central nervous system, for which there is currently no cure. In Brazil, MS prevalence is estimated to range from 1.36-20 per 100,000 inhabitants. GrowBlox Sciences, Inc. (OTCQB: GBLX) announced earlier this month, filing the second in a series of patent applications for life science inventions by its wholly-owned subsidiary, Growblox Life Sciences, LLC. Inflammatory disorders represent a serious health and economic burden in the US with over $200 billion spent annually. GB Sciences' novel cannabis-based therapies could significantly help both patients and society. According to the CDC, arthritis affects 22.7% (52.5 million) of adults in the US (2010-2012), and the prevalence is projected to increase to an estimated 26% (78 million of the projected total adult population) by 2040. DISCLAIMER: MarketNewsUpdates.com (MNU) is a third party publisher and news dissemination service provider, which disseminates electronic information through multiple online media channels. MNU is NOT affiliated in any manner with any company mentioned herein. MNU and its affiliated companies are a news dissemination solutions provider and are NOT a registered broker/dealer/analyst/adviser, holds no investment licenses and may NOT sell, offer to sell or offer to buy any security. MNU's market updates, news alerts and corporate profiles are NOT a solicitation or recommendation to buy, sell or hold securities. The material in this release is intended to be strictly informational and is NEVER to be construed or interpreted as research material. All readers are strongly urged to perform research and due diligence on their own and consult a licensed financial professional before considering any level of investing in stocks. All material included herein is republished content and details which were previously disseminated by the companies mentioned in this release. MNU is not liable for any investment decisions by its readers or subscribers. Investors are cautioned that they may lose all or a portion of their investment when investing in stocks. For current services performed MNU has been compensated three thousand nine hundred dollars for news coverage of the current press release issued by Puration, Inc. by a non-affiliated third party. MNU HOLDS NO SHARES OF ANY COMPANY NAMED IN THIS RELEASE. This release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. "Forward-looking statements" describe future expectations, plans, results, or strategies and are generally preceded by words such as "may", "future", "plan" or "planned", "will" or "should", "expected," "anticipates", "draft", "eventually" or "projected". You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a company's annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and MNU undertakes no obligation to update such statements.
News Article | February 20, 2017
BERLIN & PLEASANTON, Calif.--(BUSINESS WIRE)--ManageEngine, the real-time IT management company, today announced that NetFlow Analyzer, its traffic management software, now supports deep packet inspection (DPI). DPI support provides enhanced visibility that admins need to compare network and application response times and quickly determine whether the fault is with the network or application. In addition, NetFlow Analyzer now also supports Meraki devices to monitor their traffic flows. ManageEngine, a longtime technology partner of Cisco, will be demonstrating the new features of NetFlow Analyzer and its integrated IT operations management suite, OpManager Plus, in booth E77 at Cisco Live being held in Berlin, Feb. 20-24, 2017. “When it comes to network diagnostics, more is always better. After the initial troubleshooting via SNMP and flow-based analysis, enterprises turn to actual packet-based forensics for deeper network problems. That’s why we are adding DPI support in NetFlow Analyzer and our integrated tool OpManager Plus,” said Dev Anand, director of product management at ManageEngine. “With DPI, OpManager Plus and NetFlow Analyzer customers can now store actual application response time vs. network response time data for forensic study at a later point. The integrated suite also makes it possible to correlate packet data with monitoring data across several parameters at the same time.” With NetFlow Analyzer’s DPI monitoring, admins can keep track of the performance and network latency of business-critical applications. Whenever a slowness issue arises, they can compare the network response time (NRT) with the application response time (ART) to determine where the issue is. NetFlow Analyzer provides insightful data such as NRT and ART, traffic, source and destination, and conversation for Layer 4 applications. It offers various reports and options to help you ascertain what is causing the slowness with conversation details. These insights help admins identify performance issues at an early stage and control them with traffic-shaping techniques for an improved user experience. Meraki offers a wide range of hardware that helps to meet the ever-growing demand for wireless networks. It’s one of the leading vendors in the market and is used by many enterprises. To ease the management of Meraki devices and monitor the traffic flow, NetFlow Analyzer has brought in the support. NetFlow Analyzer monitors traffic on Meraki devices using NetFlow v9. It provides real-time traffic data on top applications, source-destination and interfaces. It allows admins to create alert profiles to get instant notification through email and SMS about traffic threshold violations. NetFlow Analyzer version 12 is available immediately for download at https://www.manageengine.com/netflow/download.html. Pricing starts at $49,995 for the Distributed edition, which supports unlimited interfaces. For SMEs, the Essential edition is offered and starts at $495 for 10 interfaces. For more information on the DPI feature, visit https://www.manageengine.com/products/netflow/deep-packet-inspection.html. ManageEngine NetFlow Analyzer is a powerful traffic analytics and network forensics tool that supports IPv6. It has other capabilities such as traffic shaping, IP SLA reporting, QoS reporting, Medianet reporting, WAAS reporting, and more. NetFlow Analyzer can be upgraded to OpManager Plus, a network management solution. For more information, please visit https://www.manageengine.com/netflow. ManageEngine delivers the real-time IT management tools that empower IT teams to meet organizational needs for real-time services and support. Worldwide, established and emerging enterprises — including more than 60 percent of the Fortune 500 — rely on ManageEngine products to ensure the optimal performance of their critical IT infrastructure, including networks, servers, applications, desktops and more. ManageEngine is a division of Zoho Corporation with offices worldwide, including the United States, India, Singapore, Japan and China. For more information, please visit http://www.manageengine.com/; follow the company blog at http://blogs.manageengine.com/, on Facebook at http://www.facebook.com/ManageEngine and on Twitter @ManageEngine. ManageEngine is a trademark of Zoho Corporation. All other brand names and product names are trademarks or registered trademarks of their respective companies.
News Article | February 24, 2017
Receive press releases from Aspose Pty Ltd: By Email It has included support for Microsoft SQL Server Reporting Services 2016. Users can now develop their reports in SSRS 2016 with barcode in it. The other major development in this release is integration of Aspose.Barcode in Visual Studio 2015. It also enhanced Processing of setting Margins and padding, previewing Barcde properties in design view, Processing of barcode Alignment and Barcode text generation process for PDF417 coded barcode and many more. Lane Cove, Australia, February 24, 2017 --( The Aspose team is happy to announce the new release of Aspose.BarCode for Reporting Services 17.1.0. The major development in this release is integration of Aspose.Barcode in Visual Studio 2015. Support of Aspose.Barcode for SSRS 2016 has also been incorporated in this release. Aspose.BarCode for Reporting Services now working with Visual Studio 2015. Users can load the Aspose.BarCode.ReportingServices.dll into Visual Studio 2015 toolbox and design the SQL report with barcode in it. The Aspose team has added support of Microsoft SQL Server Reporting Services 2016. Users can now develop their reports in SSRS 2016 with barcode in it. There are some important enhancement part of this release, such as Process of integrating Aspose.BarCode into Microsoft Visual Studio, Process of setting Margins and padding, previewing Barcde properties in design view, Processing of barcode Alignment, Functionality of barcode control in SSRS on Visual Studio 2015 and Barcode text generation process for PDF417 coded barcode has been greatly improved. Below is the list of new and improved features added in this new release: • Add support Visual Studio 2015 • Support SSRS 2016 • Barcode is scaled in Design view in Visual Studio • Margins are not taking effect • Padding is not taking effect • Barcode Alignment is different in server version and deployment version • Accessing the Barcde properties in design view throw exception • Barcode Control is Inactive in SSRS on Visual Studio 2015 • Barcode is not working in Visual Studio 2015 • BarCodeBuilder does not generate CodeText for characters: "~B" and "~C" properly for PDF417 Overview: Aspose.BarCode for Reporting Services Aspose.BarCode for Reporting Services is a .NET solution for the rendering of barcode images in SQL Server 2000, 2005 & 2008 Reporting Services. It supports 29+ linear (1D) and 2D barcode symbologies including MacroPdf417, Australia Post, OneCode, Code128, Code39, PDF417, UPCA, Codabar, MSI and QR etc. Also render barcode images on reports in BMP, JPG, PNG and GIF formats. Other features include EAN-128 application identifiers, DPI resolution settings, barcode size and location adjustments. More about Aspose.BarCode for Reporting Services - Homepage of Aspose.BarCode for Reporting Services: http://www.aspose.com/products/barcode/reporting-services - Download Aspose.BarCode for Reporting Services: http://www.aspose.com/downloads/barcode/reportingservices - Online documentation of Aspose.BarCode for Reporting Services : http://docs.aspose.com/display/barcodereportingservices/Home Contact Information Aspose Pty Ltd Suite 163, 79 Longueville Road Lane Cove, NSW, 2066 Australia http://www.aspose.com/ firstname.lastname@example.org Phone: 888.277.6734 Fax: 866.810.9465 Lane Cove, Australia, February 24, 2017 --( PR.com )-- What's New in this Release?The Aspose team is happy to announce the new release of Aspose.BarCode for Reporting Services 17.1.0. The major development in this release is integration of Aspose.Barcode in Visual Studio 2015. Support of Aspose.Barcode for SSRS 2016 has also been incorporated in this release. Aspose.BarCode for Reporting Services now working with Visual Studio 2015. Users can load the Aspose.BarCode.ReportingServices.dll into Visual Studio 2015 toolbox and design the SQL report with barcode in it. The Aspose team has added support of Microsoft SQL Server Reporting Services 2016. Users can now develop their reports in SSRS 2016 with barcode in it. There are some important enhancement part of this release, such as Process of integrating Aspose.BarCode into Microsoft Visual Studio, Process of setting Margins and padding, previewing Barcde properties in design view, Processing of barcode Alignment, Functionality of barcode control in SSRS on Visual Studio 2015 and Barcode text generation process for PDF417 coded barcode has been greatly improved. Below is the list of new and improved features added in this new release:• Add support Visual Studio 2015• Support SSRS 2016• Barcode is scaled in Design view in Visual Studio• Margins are not taking effect• Padding is not taking effect• Barcode Alignment is different in server version and deployment version• Accessing the Barcde properties in design view throw exception• Barcode Control is Inactive in SSRS on Visual Studio 2015• Barcode is not working in Visual Studio 2015• BarCodeBuilder does not generate CodeText for characters: "~B" and "~C" properly for PDF417Overview: Aspose.BarCode for Reporting ServicesAspose.BarCode for Reporting Services is a .NET solution for the rendering of barcode images in SQL Server 2000, 2005 & 2008 Reporting Services. It supports 29+ linear (1D) and 2D barcode symbologies including MacroPdf417, Australia Post, OneCode, Code128, Code39, PDF417, UPCA, Codabar, MSI and QR etc. Also render barcode images on reports in BMP, JPG, PNG and GIF formats. Other features include EAN-128 application identifiers, DPI resolution settings, barcode size and location adjustments.More about Aspose.BarCode for Reporting Services- Homepage of Aspose.BarCode for Reporting Services: http://www.aspose.com/products/barcode/reporting-services- Download Aspose.BarCode for Reporting Services: http://www.aspose.com/downloads/barcode/reportingservices- Online documentation of Aspose.BarCode for Reporting Services : http://docs.aspose.com/display/barcodereportingservices/HomeContact InformationAspose Pty LtdSuite 163, 79 Longueville RoadLane Cove, NSW, 2066Australiahttp://email@example.comPhone: 888.277.6734Fax: 866.810.9465 Click here to view the list of recent Press Releases from Aspose Pty Ltd
News Article | February 22, 2017
BANGALORE and SANTA CLARA, California, February 22, 2017 /PRNewswire/ -- - Support for IPv6, Application Visibility and Control, REST and Tosca interfaces, OpenStack Tacker integration - New Application Visibility and Control framework offers DPI capabilities at line rates per CPU...
News Article | February 22, 2017
— The Non-Invasive Prenatal Testing Market report titled “Non-Invasive Prenatal Testing (NIPT) Market Analysis, Market Size, Test Analysis, Country Outlook, Growth Potential, Competitive Strategies and Forecasts, 2017 To 2021” is a professional and in-depth study on the present market scenario of the global Non-Invasive Prenatal Testing (NIPT) Industry. The report summarizes key statistics of the market and the overall status of the Non-Invasive Prenatal Testing (NIPT) Market manufacturers. The Potential Non-Invasive Prenatal Testing (NIPT) Market is expected to reach more than USD 4 Billion across the 15 major markets (15MM) by the year end of 2021. Long–term Growth Projection: More than 2.5 Million tests will be conducted by the 11 major NIPT test by the year end of 2021. Non-Invasive Prenatal Testing (NIPT) market size was valued at nearly USD 1 Billion in 2016 and market is expected to grow at the CAGR of XX% during 2017-2021. The market growth can be attributed to factors such as high incidence rate of babies born with Down syndrome, no risk of miscarriage with NIPT and shifting trend towards child bearing at advanced maternal age (35 years or older). With increased patient access to NIPT test, the NIPT test market is anticipated to have a positive outlook in the coming years. High test cost, strict regulatory requirements and ethical hurdles is restraining the growth of NIPT test market. NIPT Test Market: Test–wise Outlook: Natera Panorama test will lead the NIPT test market with the market share of more than 25% by the year end of 2021. MaterniT21 Plus and Bambini test have shown its potential to become 2nd and 3rd popular NIPT test. Harmony test is the fourth leading test in the NIPT test market. NIFTY and Verifi test hold the fifth and sixth highest share of the NIPT test market. Other emerging tests such as Prena, IONA, VisibiliT, Veracity and informaseq NIPT test which is likely to affect the market share during the forecast period. NIPT Test Market: Country–wise Outlook: United States is the most attractive market with market share of more than 50% in 2016. China will be the second largest market for NIPT test which is expected to grow at a CAGR of XX% by 2021. United Kingdom is expected to be third largest NIPT test market being followed by Germany by the end of the forecasted period. This is the 3rd edition report on NIPT Test Market by DPI Research. The research report presents a comprehensive assessment of the market and contains thoughtful insights, facts, historical data, and statistically supported and industry–validated market data. It also contains projections using a suitable set of assumptions and methodologies. The research report provides analysis and information according to categories such as market segments, country wise actual and potential market, NIPT test analysis with volume and market revenue and competitive landscape. The report also covers market growth drivers, challenges, current and upcoming trends of the NIPT test market. Global Non-Invasive Prenatal Testing (NIPT) Market Segmentation Global Non-Invasive Prenatal Testing (NIPT) Market – By Test Type: MaterniT21 PLUS, Harmony, NIFTY, Verifi, Panorama, PrenaTest, BambniTest, informaSeq, VisibiliT, Veracity, IONA Test. Global Non-Invasive Prenatal Testing (NIPT) Market – By Country: United States, United Kingdom, Germany, Italy, Spain, France, Switzerland, Sweden, Belgium, Australia, New Zealand, Japan, China, India, Brazil. Table of Contents Non-Invasive Prenatal Testing (NIPT) Market Analysis, Market Size, Test Analysis, Country Outlook, Growth Potential, Competitive Strategies and Forecasts, 2017 To 2021: Executive Summary Global Non–Invasive Prenatal Testing (NIPT) Market Analysis (2011 – 2021) Global Non–Invasive Prenatal Testing (NIPT) Market Share Analysis (2011 – 2021) Global Non–Invasive Prenatal Testing (NIPT) Market – Geographical Segment (2013 – 2021) Global Non–Invasive Prenatal Testing (NIPT) Market – By Test (2011 – 2021) Competitive Landscape Non–Invasive Prenatal Testing (NIPT) Implementation Global Non–Invasive Prenatal Testing Market – Growth Drivers Global Non–Invasive Prenatal Testing Market – Challenges List of Tables Table 3 –1: By Country – NIPT Test Volume Share (Percent), 2013 – 2016 Table 3 –2: By Country – Forecast for NIPT Test Volume Share (Percent), 2017 – 2021 Table 3 –3: By Country – NIPT Test Actual Market Share (Percent), 2013 – 2016 Table 3 –4: By Country – Forecast for NIPT Test Actual Market Share (Percent), 2017 – 2021 Table 3 –5: By Country – NIPT Test Potential Market Share (Percent), 2013 – 2016 List of Figures Figure 2 –1: By Country – NIPT Test Outlook (Number), 2013 – 2016 Figure 2 –2: By Country – Forecast for NIPT Test Volume Outlook (Number), 2017 – 2021 Figure 2 –3: By Country – NIPT Test Actual Market Outlook (Million US$), 2013 – 2016 Figure 2 –4: By Country – Forecast for NIPT Test Actual Market Outlook (Million US$), 2017 – 2021 Figure 2 –5: By Country – NIPT Test Potential Market Outlook (Million US$), 2013 – 2016 About Us: ReportsnReports.com is a single source for all market research needs. Our database includes 500,000+ market research reports from over 95 leading global publishers & in-depth market research studies of over 5000 micro markets. For more information, please visit http://www.reportsnreports.com/reports/805854-non-invasive-prenatal-testing-nipt-market-analysis-market-size-test-analysis-country-outlook-growth-potential-competitive-strategies-and-forecasts-2017-to-2021.html
News Article | March 2, 2017
DPI Research has announced the addition of the "United States Insulin Pump Market & Forecast to 2022" report to its offering